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Abstract
Background: Total costs associated with care for older people nearing the end of life and the cost variations related
with end of life care decisions are not well documented in the literature. Healthcare utilisation and associated health
care costs for a group of older Australians who entered Transition Care following an acute hospital admission were
calculated. Costs were differentiated according to a number of health care decisions and outcomes including advance
directives (ADs).
Methods: Study participants were drawn from the Coaching Older Adults and Carers to have their preferences Heard
(COACH) trial funded by the Australian National Health and Medical Research Council. Data collected included total
health care costs, the type of (and when) ADs were completed and the place of death. Two-step endogenous treatment-
regression models were employed to test the relationship between costs and a number of variables including
completion of ADs.
Results: The trial recruited 230 older adults with mean age 84 years. At the end of the trial, 53 had died and 80 had
completed ADs. Total healthcare costs were higher for younger participants and those who had died. No statistically
significant association was found between costs and completion of ADs.
Conclusion: For our frail study population, the completion of ADs did not have an effect on health care utilisation and
costs. Further research is needed to substantiate these findings in larger and more diverse clinical cohorts of older people.
Trial registration: This study was registered on 13/12/2007 with the Australian New Zealand Clinical Trial Registry
(ACTRN12607000638437).
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Background
Australia has a rapidly ageing population with 14 %
being over the age of 65 in 2012 (15 % and 13 % for
women and men, respectively) [1, 2] with this figure set
to rise to 22 % by 2061 [1]. Older people nearing the
end of life are susceptible to multiple comorbid illnesses
including neurodegenerative disorders that cause impair-
ments in motor and sensory functioning, mobility and
balance as well as chronic conditions such as diabetes,
arthritis and cardiovascular disease [3–5]. Many of these
comorbidities lead to reduced functional status in older
people: chronic disease burden, impaired cognition, dia-
betes and arthritis all increase the risk of falls [6–10].
Older people aged between 65 and 75 years are twice as
likely in South Australia to be admitted to a hospital
compared to the general population while those aged
over 85 are five times more likely [11]. In addition,
approximately 80 % of all deaths in Australia in 2012
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were attributable to people aged over 65 years experien-
cing chronic disease as the leading cause of their death
[12, 13]. Further, Australian studies indicate that the
majority of older people die in a hospital or another in-
stitutional setting and yet this is not the place they
would have chosen to die [14].
Many older people nearing the end of life may be un-
able to make health or other personal decisions due to
factors that may inhibit their ability to do so including
impaired cognition and decision-making capacity [15].
Substitute decision makers (SDMs), such as family mem-
bers, carers or healthcare providers, may be required to
make decisions for the person at this time and these
decisions are often made in an emotional climate [16].
In recent years in Australia, there has been growing
interest in end of life care plans or Advance Directives
(ADs) to help individuals to make their preferences
known when they no longer have an ability to do so
[17]. Advance directives are documents that provide the
opportunity for people to make instructional decisions
and/or nominate SDMs for the future ensuring that their
preferences can be known and respected at the time of
incapacity [17]. Prior to July 2014, South Australia had
four legal ADs: Enduring Power of Attorney (EPA),
Enduring Power of Guardianship (EPG), Medical Power
of Attorney (MPA) and Anticipatory Direction [18, 19].
Under the Advance Care Directives Act 2013 (SA), the
EPG, MPA and Anticipatory Direction were replaced
with a new Advance Care Directive form, which was im-
plemented in July 2014. Some non-legal ADs also exist
and may form part of an overall advance care plan, such
as the Good Palliative Care Plan (GPCP) produced by
Palliative Care Australia [20] and the Statement of
Choices document (SOC) which is part of the Respect-
ing Patient Choices Program [21]. Non-legal ADs are
usually care plans created for a person during a process
whereby individuals in consultation with health care
providers and relatives, describe their personal values
and life goals and these help inform healthcare and life-
style decisions at times of future health care need [22].
Documenting ADs enables alignment of decision-
making to support personal autonomy of individuals
with decision-making by families and other decision-
makers and has been demonstrated to increase satisfac-
tion with care [23–25].
A number of international studies have documented
the relationship between ADs and healthcare costs
[26–38]. And while some generic end-of-life-care lit-
erature [35, 39] suggests a pattern of higher health
care expenditures and service utilisation for older
people nearing the end of life relative to costs earlier
in life, research specifically documenting the impact
of ADs on healthcare costs indicates that use of ADs is
either associated with lower healthcare costs [26, 29, 32,
36–38] or does not have an impact on these costs [27, 28,
30, 31, 33–35]. Explanations for these results vary. In a
study of consecutive American patients who died in a uni-
versity tertiary care medical centre, Weeks et al. [29] for
instance suggested that lower costs for decedents with a
previously completed AD could have been due to this
group preferring to limit their care while Nicholas et al.
[32], based on a study of decedent Medicare beneficiaries,
found that such treatment-limiting ADs only had a signifi-
cant impact in high spending regions characterised by
aggressive end-of-life-care. Tan and Jatoi [30], drawing on
a sample of cancer patients, concluded that those with
ADs had no significant difference in cost from those
patients without ADs because a substantial proportion of
these ADs lacked specifics about end of life care and
therefore did not lead to significant changes in patient
care. A similar result was found in the ‘Study to Under-
stand Prognoses and Preferences for Outcomes and Risks
of Treatments’ (SUPPORT) trial and Teno and colleagues
et al. [31] suggested that this lack of association, and in
particular that of ADs not being associated with decreased
costs, was reassuring as the “…primary purpose of ADs is
to convey patient preferences and instructions to guide fu-
ture care during a period of mental incapacity, not to save
scarce societal resources.” However, little research has
been conducted to assess actual health care utilisation and
health care expenditures within an Australian setting for
older people nearing the end of life who have used ADs.
This paper reports on research designed to examine the
relationship between healthcare costs and completed ADs
whilst controlling for the effect of other factors such as
health-related quality of life, demographic characteristics,
mortality and place of death. In this study, we also instru-
ment or control for the decision to complete ADs as some
factors such as age, gender and quality of life (QoL) have
been shown to influence this decision [19, 40–42]. To our
knowledge, this is the first time that this type of analysis
has been completed for a cohort of frail older people in
Australia. The results of this study will be helpful to policy
makers and others with regard to the total costs associated
with care for older people nearing the end of life and the
cost variations related with end of life care decisions.
Methods
This study was approved by the Research Ethics Com-
mittee at the Repatriation General Hospital in Adelaide
(approval no. 90/07) and written informed consent was
obtained from all participants.
Data source
Data for this secondary study were obtained from the
Coaching Older Adults and Carers to have their prefer-
ences Heard (COACH) randomised controlled trial, the
methodological details of which have been reported
Kaambwa et al. BMC Health Services Research  (2015) 15:545 Page 2 of 12
elsewhere [43]. Briefly, the aim of the primary study (the
COACH trial) was to determine whether a coaching
intervention delivered by a geriatrician and specialist
nurse in a post hospital (intermediate) care setting
improved older adults’ and carers’ assessment of the
quality of preparation for transfers. This intervention
included questions on completion of ADs including
the GPCP, EPGs and other non-GPCP and non-EPG
medical documents (MDs). A total of 230 older adults
admitted to Transition Care (a type of intermediate
care) in Adelaide, Australia were randomised into the
intervention (116) or usual care (114) arms. To be
eligible, participants needed to be identified from con-
secutive admissions to a single residential Transition
Care (TC) facility, able to communicate in English
and nominate an informal carer willing to participate
in the study. The Australian TC Program provides
support for older people at the conclusion of a hos-
pital stay and can be provided in a residential or
community setting [44]. All participants received
usual care, delivered by a multidisciplinary team at a
TC facility, made up of comprehensive geriatric as-
sessment, care plans and periodic review at regular
case conference meetings [43, 45]. A comprehensive
geriatric assessment was carried out in both arms of
the COACH trial and included the use of the inter-
RAI Post-Acute Care Assessment instrument [46] as
well as a question about the existence of legal docu-
ments including ADs. If a participant was identified
as palliative and had not completed an AD, TC
nurses initiated a discussion with the older person
about their preferences for end of life care and a geri-
atric registrar completed the consultation and signing
of the GPCP.
Participants allocated to the intervention group re-
ceived a coaching intervention that comprised four add-
itional components: a question prompt list used a week
before a geriatric consultation in order to enhance
patient participation during the consultation; geriatric
consultations with a geriatrician and nurse covering sev-
eral topics included on a checklist; a written summary of
every consultation; and a follow-up telephone call two to
three weeks post discharge [43]. The question prompt
list included a prompt about EPAs and EPGs while the
checklist for the geriatric consultation included a
prompt to discuss end of life care plans and consider
completion of a GPCP.
There are several different types of legal and non-legal
ADs including the GPCP (non-legal) and EPG (legal)
that were documented in this study. The GPCP docu-
ments a person’s preferred medical treatment to be pur-
sued once they have been designated palliative while the
EPG is a document which appoints and instructs a sub-
stitute decision-maker (e.g. friend or family member) to
make decisions concerning the person’s health, resi-
dential and lifestyle care should the person be unable
to make these decisions [47]. There were also a number of
other MDs comprising both legal and non-legal ADs (e.g.
Anticipatory Directions, Medical Power of Attorney, Liv-
ing Wills) that patients completed which either specified
the types of medical treatment the person did or did not
want at times of decision-making incapacity or nominated
a substitute decision-maker [47]. Information on whether
these ADs were completed before or during the trial
was also collected. This study documents the last
ADs that were in place for study participants and
focused on the categories of GPCPs, EPGs or MDs
(non-GPCP, non-EPG).
Self-reported patient outcome measures
These measures were collected at baseline, 3 and
12 months and included QoL as measured by the Euro-
QoL EQ-5D 3 level (EQ-5D 3 L) instrument [48] and
functional status assessed using the modified Barthel
Index [49]. The difference in EQ-5D 3 L scores between
baseline and 12 months was used to generate a ‘QoL
change’ variable. Geriatric Depression Scale (GDS‐15)
scores for measuring depressive symptoms [50] were
also gathered at baseline and 12 months and mortality
data were collected at 3 and 12 months. Other informa-
tion was collected at baseline only and this included data
on cognitive status as assessed by the Standardised Mini
Mental State Examination (SMMSE) [51] and body mass
index (BMI). On discharge from TC, information on
whether, the type and when the ADs had been com-
pleted was extracted from the TC facility records.
Cost analysis
Costs were analysed from a health sector perspective.
Within the COACH trial, Medicare costs for out-of-
hospital visits were estimated using the Medicare Bene-
fits Scheme (MBS) public subsidy (the Medicare benefit)
paid for each of these items. Medicare costs for out-of-
hospital visits included costs for tests, treatments and
investigations; medical consultations and costs for
primary care and general practice visits (Other). For in-
patient hospital admissions, data on the diagnosis related
group (DRG) associated with each admission as well as
the length of stay were collected from hospitals. Using
the Australian Refined Groups DRG cost weights [52], a
cost per day for each DRG was established and this was
multiplied by patient level data capturing the length of
stay for each DRG-associated admission within the
COACH data in order to obtain a total cost for in-
hospital admissions. Medicare drug costs were estimated
using the Pharmaceutical Benefits Scheme (PBS) public
subsidy (the Pharmaceutical benefit) paid for each of
the drugs used. Resource use data collected for the
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intervention included staff time spent by geriatricians
and nurses, equipment, overheads and other supplies
used. Salary costs for staff, unit costs for equipment,
overheads and supplies were obtained locally from hos-
pital finance departments.
All costs were reported in Australian dollars at 2013/
14 unit prices and discounting was not necessary as the
follow up period was less than one year [53].
Statistical analysis
Descriptive statistics (means and standard errors) were
generated and simple statistical tests of differences that
took into account the distributional nature of the
variables in the dataset (Kruskall Wallis and Pearson
chi-square tests) were also carried out [54]. Differences
in demographic and other participant characteristics
according to whether or not ADs were completed were
tested. A two-step endogenous treatment-regression
approach was used in our analysis [55]. In the first step,
the decision to complete an AD was predicted from a
number of factors identified in the literature [19, 40–42]
including age, gender and quality of life status using a
probit regression model. This was because we assumed
that AD completion was endogenous with the decision
to complete/not complete ADs ultimately affecting
healthcare costs. Not accounting for this endogeneity, if
present, leads to biased estimates related to Type I and
Type II errors [55, 56]. In the second step, a linear
regression model was utilised to ascertain whether a
number of independent variables (including the hazard
or probability of completing ADs obtained from the first
step) were jointly predictive of lower or higher health
care costs on average [55]. The endogenous treatment-
regression approach allowed the modelling of a specific
correlation structure between the unobservables that
affect the decision to complete ADs and those that affect
variation in healthcare costs [55–58]. Because our ana-
lysis distinguished between seven types of healthcare
costs (i.e. costs for drugs; hospitalisation, tests, treat-
ments and investigations; consultations, general practice
visits and total costs (unadjusted and adjusted for cen-
soring), we fitted seven two-step regression models using
the ‘etregress’ command in Stata [59]. In line with
standard practice in analyses such as ours, independent
variables included in each final model were chosen on
theoretical grounds (i.e. documented or postulated rela-
tionships with the dependent variable) as well as on the
basis of their ability to improve the model fit [60]. As
there were missing data on some costs and other patient
variables (Table 1), multiple imputation [61] was used to
account for missing values prior to examining the rela-
tionship between costs and other patient characteristics.
The imputation procedure used an iterative Markov
chain Monte Carlo method based on a multivariate
normal regression [62] and involved replacing each
missing value in the dataset with a set of 20 plausible
values that represented the uncertainty about the right
Table 1 Baseline characteristics by whether participants had
advance directive completions
Variable ADa
completed
ADa not
completed
Entire
sample
n = 76 n = 152 n = 228
mean (SD) mean (SD) mean (SD)
Age (in years)* 85.76 (7.02) 83.31 (6.88) 84.13 (7.01)
Baseline QoLb (EQ-5D
3 L score)*
0.41 (0.31) 0.49 (0.29) 0.46 (0.30)
Baseline functional status
(Barthel Index)
57.46 (21.4) 60.99
(20.70)
59.81
(20.95)
Baseline cognitive function
SMMSEc score)
22.24 (5.54) 23.63 (4.97) 23.17 (5.22)
Baseline depressive symptoms
(GDS-15d score)*
5.84 (2.97) 4.30 (2.97) 4.80 (3.05)
Body mass index (BMI)e 24.03 (5.79) 24.47 (5.86) 24.32 (5.83)
n (%) n (%) n (%)
Gender (female) 44 (58) 94 (62) 138 (61)
Individuals with a QoLf gain
over 12 months
28 (42) 67 (48) 95 (46)
Individuals dead at
12 months
18 (24) 35 (23) 53 (23)
Place of death
Hospital 10 (56) 21 (60) 31 (58)
Residential Care/Respite 8 (44) 11 (31) 19 (36)
Home/Independent 0 (0) 3 (9) 3 (6)
Living unit
Type of ADa completed (%)
GPCPg 35 (46)
EPGh 21 (28)
MDi 20 (26)
When AD was completedj
Before admission to TCk 22 (30)
During admission to TCk 51 (70)
Trial Arm
Intervention* 53 (70) 63 (41) 116 (51)
Usual care* 23 (30) 89 (59) 112 (49)
aAD = Advance directive
bQoL = Quality of life
cSMMSE = Standardised Mini Mental State Examination (SMMSE)
d GDS-15 = Geriatric Depression Scale. Due to missing data, n = 78 for AD
completers and n = 147 for AD non-completers
eThere was some missing data on the BMI and therefore n = 79 for AD
completers and n = 140 for non-completers
fQoL = Quality of life. Due to missing data, n = 71 for AD completers and
n = 137 for AD non-completers
gGPCP = Good palliative care plan
hEPG = Enduring power of guardianship
iMD =Medical documentation
jSome data missing on when the AD was completed were missing for n = 4
COACH participants
kTC = Transition care
*Kruskall Wallis test statistically significant at 0.05
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value to impute [61]. The 20 resultant multiply imputed
datasets were then analysed using standard complete-
case procedures and the results combined using Rubin’s
rules [63]. The regressions for total costs was also later
adjusted for censoring using Lin’s method [64]. A signifi-
cance level threshold of 5 % (0.05) was assumed as the
criterion for determining statistical significance in all
analyses [65]. All analyses were conducted in Stata ver-
sion 13.1 [59].
Results
Recruitment ended when the target recruitment level
(determined through sample size calculation) for the
COACH trial of 230 older adults, who were followed up
to 12 months, was reached [43]. Two individuals were
not registered for Medicare benefits and so were ex-
cluded from the analysis. Table 1 shows the descriptive
results from the total sample (n = 228). At baseline, indi-
viduals had a mean age of 84.1 years and mean EQ-5D
3 L, Barthel and SMMSE scores of 0.46, 59.8 and 23.2,
respectively. The baseline GDS-15 mean score was 4.8
while that for BMI was 24.3. The majority of participants
in the study sample were female (n = 138, 61 %) and, at
the end of the 12 months follow up period, the majority
remained alive (n = 175, 77 %) while nearly half (95,
46 %) registered a QoL improvement according to the
EQ-5D 3 L (mean EQ-5D 3 L improvement over
12 months of 0.33). Of the 23 % (n = 53) of individuals
who had died at the end of the study, almost all died
within a hospital (n = 31, 58 %) or in a residential aged
care or respite facility (n = 19, 36 %). For some dece-
dents, the place of death was also the first discharge des-
tination from TC. For instance, the first discharge
destination post-TC for 12 (39 %) of the decedents who
died in hospital was readmission to hospital while 10
(53 %) of those who died in a residential aged care or
respite facility were first discharged to a residential aged
care facility (results not shown in Table 1). Of the total
sample, 76 (33 %) completed ADs with the majority of
these completing a GPCP (n = 35, 44 %) and almost
equal numbers completing either an EPG (n = 21, 26 %)
or an MD (n = 20, 25 %). Eighteen of the 53 decedents
(34 %) had completed ADs (results are shown in
Table 1).
Compared to those who did not complete ADs (mean
scores in Table 1), individuals who did so were, on aver-
age, older (85.8 vs 83.3 years) and had slightly lower
QoL and functional status (0.41 vs 0.49 and 57.5 vs 61.0
for EQ-5D 3 L and Barthel scores, respectively). The AD
completers also had marginally lower SMMSE and BMI
scores (22.2 vs 23.6, 24.0 vs 24.5, respectively), higher
GDS-15 scores (5.8 vs 4.3) and were much more likely
to be in the intervention group (70 % vs 30 %). The
completion rate in the intervention group was higher
than that in the usual care group (46 % vs 20 %). All dif-
ferences were statistically significant except those for the
Barthel, SMMSE and BMI scores. There was no statisti-
cally significant difference between those that completed
ADs and those that did not in terms of gender, propor-
tions that had registered QoL improvements or had died
at the end of the study (12 months) or in relation to
place of death. Though there was no statistically signifi-
cant association between completing ADs and when
these ADs were completed (i.e. before or during admis-
sion to a TC), results not presented in Table 1 showed
that among AD completers, the time of completion dif-
fered statistically according to trial arm. In particular,
76 % of AD completers in the intervention arm com-
pleted these documents during admission to TC com-
pared to 55 % in the control arm. As shown in Table 2,
AD completers (defined according to type of AD com-
pleted) differed significantly by SMMSE score (lower
scores being associated with completion of EPG) and by
trial arm (majority of GPCP (86 %) and EPG (67 %)
completers were in the intervention arm while majority
of individuals who completed MDs were in the control
arm). There were trends for individuals who completed
an EPG to be female (p = 0.06) and younger (p = 0.09).
There were no statistically significant relationships
between the type of AD completed and any other
variables.
Table 3 shows the bivariate relationship between costs
and a number of patient characteristics. Multiple impu-
tations were used to account for missing data on the
GDS-15 (1 %), BMI (4 %), EQ-5D 3 L (9 %), when ADs
were completed (2 %) and costs (16 %). And as the re-
sults for the imputed data were similar to those based
on unimputed data, we only show the former in the
paper. The only costs that differed according to whether
or not one had completed ADs (and type of AD com-
pleted) were costs of the COACH intervention – higher
for those who completed ADs ($274 vs $149) and higher
for individuals who completed GPCPs and EPGs in par-
ticular ($359 and $262, respectively vs $168 for MDs). In
a sensitivity analysis, four individuals, considered to be
outliers, were excluded due to extremely high total costs
of over $30,000 per individual. The exclusion of these
four reduced the difference in total health care utilisa-
tion costs between ADs completers and non-completers
to approximately $15,000 per patient. In addition to total
costs, the type of costs that differed significantly based
on gender (higher for males) were those for hospitalisa-
tions, tests, treatments and investigations. Pharmaceut-
ical costs for clients who recorded a QoL improvement
at the end of 12 months were also significantly lower
than those for individuals who recorded no change or
QoL deterioration. Some costs also differed according
to whether or not the patient had died at the end of
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12 months. These were costs for drugs, hospitalisation,
GP and other primary care visits (other costs) and
total costs. In general, decedents exhibited higher
total and hospitalisation costs but lower pharmaceut-
ical and other costs.
Table 4 reports the results of a series of the two-step
endogenous treatment-regressions are based on multiply
imputed data as well as on data that were adjusted for
censoring. The results of the first step show that the
probability of completing ADs increased as people aged,
experienced a rise in depressive symptoms (as measured
by the GDS-15) and was also higher among females
compared to males. The results from the second step
indicate that being older was associated with lower
healthcare costs for all type of costs except for ‘GP and
primary care visit costs’ that were higher for older
people. Further, a higher BMI was predictive of higher
pharmaceutical costs while a higher SMMSE and having
recorded a QoL gain at 12 months were associated with
higher costs for tests, treatments and investigations. A
higher SMMSE score was also indicative of higher costs
for consultations. Lastly, decedents at 12 months were
associated with higher GP and primary care visit costs.
Data on four clients who withdrew from the study were
censored. The regression model with multiple imputed
data and adjustment for censoring showed, as above, a
negative relationship between total costs and age but
also showed that higher total costs were associated with
being a decedent at 12 months. No statistically signifi-
cant relationship was seen between completing ADs and
any of the costs in all the models above.
Discussion
Our sample was made up of older people in TC, a type
of intermediate care, at risk of readmission to hospital
and death within the following 12 months. Overall, older
Table 2 Type of advance care directive by participant characteristics
Variable GPCPa EPGb MDc
n = 35 n = 21 n = 20
Median; mean (SD) Median; mean (SD) Median; mean (SD))
Age in years 86.0; 85.0 (7.5) 87.0; 84.8 (7.2) 87.5; 88.0 (5.6)
Baseline QoLd (EQ-5D score) 0.33; 0.38 (0.33) 0.45; 0.46 (0.26) 0.38; 0.41 (0.33)
Baseline functional status (Barthel Index) 57.0; 55.5 (23.3) 61.0; 59.8 (19.2) 60.5; 58.4 (20.9)
Baseline cognitive function (SMMSEe score)* 25.0; 23.3 (5.7) 19.5; 19.2 (5.8) 23.5; 23.4 (4.3)
Baseline depressive symptoms (GDS-15f score) 6.0; 5.8 (2.7) 5.0; 5.6 (2.9) 4.5; 6.0 (3.6)
Body mass index (BMI)g 22.2; 23.6 (6.5) 24.0; 24.9 (5.3) 22.9; 23.9 (5.0)
Gender [n,(%) male] 15 (43) 12 (57) 5 (25)
n (%) who had a QoLh gain over 12 months 13 (41) 7 (41) 8 (44)
n (%) who had died at the end of 12 months 10 (29) 6 (29) 2 (10)
Place of death [n (%) in each column]
Hospital 6 (60) 3 (50) 1 (50)
Residential Care/Respite 4 (40) 3 (50) 1 (50)
Home/Independent living unit 0 0 0
When AD was completedi
Before admission to TCj 0 17 (81) 5 (25)
During admission to TCj 35 (100) 2 (10) 15 (70)
Trial Arm
Intervention* 30 (86) 14 (67) 9 (45)
Usual care* 5 (14) 7 (33) 11 (55)
aGPCP = Good palliative care plan
bEPG = Enduring power of guardianship
cMD =Medical documentation
dQoL = Quality of life
eSMMSE = Standardised Mini Mental State Examination
fGDS-15 = Geriatric Depression Scale. Due to missing data, n = 34 for GPCP, 20 for EPG and 18 for MD
gThere was some missing data on the BMI: n = 34 for GPCP, = 21 for EPG & 20 for MD
hQoL = Quality of life. Because of missing data, n = 32 for GPCP, 17 for EPG and 18 for MD
iSome data on when the AD was completed were missing: n = 19 for EPG and n = 20 for MD
j TC = Transition care
*Kruskall Wallis test statistically significant at 0.05
Kaambwa et al. BMC Health Services Research  (2015) 15:545 Page 6 of 12
people who received the coaching intervention in our
study had statistically higher costs associated with com-
pleting ADs. Significantly and when compared to the
control, the intervention group had a higher rate of AD
completion as well as heavier staff involvement, which
may have contributed to the higher costs in the latter.
There was no statistically significant relationship be-
tween any other healthcare costs and completion of ADs
regardless of whether or not the effect of other factors
was controlled for. This result seems to be congruent
with other studies that suggest that the use of ADs does
not necessarily lead to significant cost savings [27, 28,
30, 31, 33–35] or to patients calling for more of the
expensive, high technology treatment often used in ter-
minal phases of illness [34]. The National Framework
for Advance Care Directives recommends making ADs a
routine part of patient contact with practitioners in
health and aged care [17] and this result suggests it may
be possible to do this in a cost neutral manner with the
focus mainly on improving the end of life for older frail
people rather than on managing costs.
The AD completion rate of 33 % in our entire sample
was lower than that reported in a systematic review of
interventions that promote ADs among older adults
internationally (45.6 %) [66] but the rate in our interven-
tion group (46 %) was comparable suggesting that the
COACH intervention was as effective as similar inter-
national interventions designed to promote AD comple-
tion rates. [66] [66] As expected, there was a higher rate
of completion for the intervention compared to usual
care within the COACH study (46 % vs 20 %). The rea-
son for this higher rate in the former was that the inter-
vention encouraged older adults to consider their
preferences for end of life care and to discuss these with
their family and consider AD completion. This was in
contrast to usual care in which these discussions were
triggered when a participant was identified as palliative.
Consequently, a higher proportion of individuals in the
intervention arm last completed an AD during, rather
than before, admission to the TC site. It is not surprising
that the majority of ADs completed were GPCPs as this
was the main ‘prompt’ document in use at the TC site.
Table 3 Costs by advance care directive completions and selected demographic characteristics (Australian dollars)
Type of costs: figures are mean (Standard deviation)
Variable Drugs Hospitalisation Tests, treatments &
Investigations
Consultations Intervention Othera Total
n = 228 n = 228 n = 228 n = 228 n = 228 n = 228 n = 228
Was an ADb completed?
Yes (n = 76) 4,605(4,949) 33,534(63,669) 3,104(4,109) 2,323(1,957) 285(212)* 172(267) 43,955(64,490)
No (n = 152) 5,648(5,794) 44,396(86,314) 3,793(6,249) 2,531(2,353) 153(210)* 181(262) 56,910(90,740)
Type of ADb completed
GPCPc (n = 35) 4,745(5,393) 30,256(44,876) 2,162(2,571) 1,843(1,694) 356(172)* 161(271) 39,423(43,911)
EPGd (n = 21) 4,867(5,866) 46,034(91,302) 3,749(5,445) 2,589(1,842) 277(228)* 159(289) 57,610(92,844)
MDe (n = 20) 4,085(2,834) 26,147(58,077) 4,076(4,529) 2,883(2,363) 172(218)* 206(248) 37,548(60,049)
Gender
Females (n = 138) 5,313(5,419) 32,305(72,418)* 2,873(3,688) 2,378(2,158) 196(218) 191(254) 43,485(74,557)*
Males (n = 90) 5,281(5,747) 53,763(88,139)* 4,622(7,611) 2,590(2,335) 199(222) 158(278) 66,557(93,207)*
Did individual have a QoL gain?
Yes (n =105) 5,242(5,866) 34,530(81,028) 4,448(7,253) 2,420(2,161) 206(221) 211(300) 47,027(87,102)
No (n = 123) 5,237(5,430) 40,390(60,029) 2,932(4,188) 2,547(2,387) 193(218) 151(231) 51,718(62,788)
Was individual dead at 12 months?
Yes (n = 53) 4,698(7,024)* 63,139(100,000)* 3,985(7,107) 2,379(2,656) 181(208) 106(210)* 74,439(110,000)*
No (n = 175) 5,483(5,012)* 34,002(70,232)* 3,436(5,112) 2,487(2,088) 202(223) 200(274)* 45,976(71,992)*
Place of death
Hospital (n =31) 4,351(7,099) 87,896(130,000) 5,034(8,793) 2,637(3,233) 223(213) 59(112) 100,000(140,000)
Residential care (n = 19) 3,931(3,109) 28,812(25,740) 1,675(1,338) 1,912(1,487) 142(197) 190(307) 36,610(27,035)
Home/Ind. living unit (n = 3) 13,141(18,044) 24,710(42,798) 7,763(6,959) 2,679(1,847) 51(88) 48,343(67,221)
Total sample 5,300(5,538) 40,775(79,507) 4,083 (5,951) 2,786 (2,256) 188 (219) 201 (279) 55,214 (88.421)
*Kruskall Wallis test statistically significant at 0.05; aOther = primary care and general practice; bAD = Advance directive; cGPCP = Good palliative care plan;
dEPG = Enduring power of guardianship; eMD =Medical documentation
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Table 4 Predictors of completing Advance Directives and Costs (based on binary and linear model regressions of multiply imputed data)
Dependent variables for 2nd step of the regression analyses are different types of costs: figures are coefficient (Std. Err.)
Independent variable Drugs Hospitalisation Tests, treatments &
Investigations
Consultations Othera Total Total (adjusted
for censoring)b
n = 228 n = 228 n = 228 n = 228 n = 228 n = 228 n = 228
Predictors of Costs
Was an ADc completed? (1 = yes; 0 = No) 0.02 (0.24) 0.93 (0.58) 0.47 (0.32) 0.22 (0.23) 0.96 (0.51) 0.64 (0.42) 0.19 (0.11)
Gender(1 = Female, 0 = Male) 0.05 (0.13) −0.20 (0.33) −0.22 (0.17) −0.06 (0.12) −0.29 (0.29) −0.17 (0.24) −0.05 (0.06)
Age (in years) −0.02 (0.01)* −0.09 (0.03)* −0.06 (0.01)* −0.02 (0.01)* 0.10 (0.03)* −0.06 (0.02)* −0.01 (0.00)*
Baseline EQ-5D 3 L score −0.15 (0.29) 0.44 (0.68) 0.44 (0.40) 0.00 (0.29) 0.27 (0.55) 0.30 (0.51) −0.05 (0.13)
Baseline Barthel Index 0.00 (0.00) −0.01 (0.01) −0.01 (0.01) 0.00 (0.00) 0.01 (0.01) −0.01 (0.01) 0.00 (0.00)
Baseline SMMSEd score 0.02 (0.01) 0.00 (0.03) 0.04 (0.02) * 0.03 (0.01) * 0.03 (0.03) 0.01 (0.02) 0.01 (0.01)
Baseline GDS-15e score 0.00 (0.02) −0.08 (0.06) 0.01 (0.03) 0.01 (0.02) −0.03 (0.05) −0.06 (0.04) −0.01 (0.01)
Body mass index 0.04 (0.01)* −0.06 (0.03) −0.01 (0.02) 0.01 (0.01) 0.03 (0.03) −0.03 (0.02) 0.00 (0.01)
Did individual have a QoLf gain at 12
months? (1 = ‘Yes’, 0 otherwise)
−0.11 (0.15) −0.20 (0.37) 0.44 (0.21) * −0.03 (0.15) 0.48 (0.28) −0.21 (0.27) −0.23 (0.17)
Dead at 12 months (1 = Yes, 0 = No) −0.19 (0.16) 0.20 (0.39) −0.05 (0.22) −0.16 (0.15) 0.74 (0.32) * 0.09 (0.29) 0.29 (0.08) *
Constant 8.98 (1.15)* 20.10 (3.15)* 13.1 (1.48)* 8.78 (1.01)* −4.99 (2.73) 17.13 (2.04) * 11.89 (0.47)*
R-Squared 0.19 0.09 0.18 0.09 0.08 0.10 0.25
The dependent variable for each type of cost in the 1st step of the regression analyses is whether or not an individual
completed an Advance Directive: figures are coefficient (Std. Err.)
Drugs Hospitalisation Tests, treatments &
Investigations
Consultations Othera Total Total (adjusted
for censoring)b
n = 228 n = 228 n = 228 n = 228 n = 228 n = 228 n = 228
Predictors of AD completion
Gender (1 = Female, 0 = Male) 0.12 (0.04)* 0.10 (0.03)* 0.12 (0.04)* 0.17 (0.05)* 0.12 (0.03)* 0.10 (0.03)* 0.12 (0.03)*
Age (in years) 0.03 (0.01)* 0.03 (0.01)* 0.03 (0.01)* 0.04 (0.01)* 0.03 (0.01)* 0.03 (0.01)* 0.04 (0.01*)
Baseline SMMSEd score −0.02 (0.02) −0.03 (0.02) −0.03 (0.02) −0.02 (0.02) −0.02 (0.02) −0.03 (0.02) −0.03 (0.02)
Baseline GDS-15e score 0.08 (0.03)* 0.09 (0.03)* 0.09 (0.03)* 0.09 (0.03)* 0.12 (0.03)* 0.09 (0.03)* 0.09 (0.03)*
constant −2.92 (1.14) −2.88 (1.16) −2.66 (1.18) −3.02 (1.19) −2.94 (1.23) −2.97 (1.15) −2.98 (1.15)
Likelihood-ratio test of independent
equations
χ2 = 18.60 χ2 = 34.24 χ2 = 46.01 χ2 = 26.12 χ2 = 9.93 χ2 = 37.21 χ2 = 38.60
(p < 0.01) (p < 0.01) (p < 0.01) (p < 0.01) (p < 0.01) (p < 0.01) (p < 0.01)
aOther = primary care and general practice; bTotal costs calculated after adjusting for censoring using Lin’s method [64]; cAD = Advance directive; dSMMSE = Standardised Mini Mental State Examination;
eGDS-15 = Geriatric Depression Scale; fQoL = Quality of life; *Statistically significant at 0.05 level
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In addition, a comparable South Australian study docu-
menting end of life decisions in residential care facilities
found a similar result [67]. Our study also showed that
34 % of decedents had completed ADs, which is compar-
able to results from similar studies that report the pro-
portion of deaths preceded by completion of any end of
life document range between 23 % (Italy) and 51 %
(Switzerland) [68]. As also noted by other Australian
studies [14], almost all individuals in our sample died in
a hospital or another institutional setting which is at
odds with people’s preferences as previously reported
[14]. Further, for some decedents, the place of death was
also the first discharge destination after TC and it is
unclear to what extent decedents’ first discharge destina-
tions and places of death represented their preferences.
As data on preferred place of death was not collected in
our study, it was not possible to empirically test whether
place of death reflected patients’ preferences. Further
research is required before strong conclusions can be
drawn on these findings.
The National Framework for Advance Care Directives
in Australia [17] reports that of people considering ADs,
10 % are near death, 30 % are chronically ill and 60 %
are well which suggests that most individuals completing
ADs are not experiencing major illness or disability.
Contrary to these findings, older people who completed
ADs in our study had lower QoL than older people gen-
erally. It is important to recognise however that our
study was completed in a residential TC setting and
study participants had a recent major illness or injury,
and significant disability that put them at risk of not
returning to live in the community. These study partici-
pants were thus are not representative of the general
older Australian population. Completion of an EPG was
associated with lower SMMSE scores indicating that in-
dividuals with greater cognitive impairment had a higher
probability of having SDMs.
The higher overall and component (hospitalisations,
tests, treatments and investigations) costs for males
compared to females may be explained by the longer in-
hospital length of stay for the former group (five days
longer on average). Total costs for decedents (driven in
a large part by hospitalisation costs) were higher (nearly
twice as high) than those for survivors and these results
were also borne out by those from international studies:
a study reported that costs for US decedents in 2004
were over six times higher than those for survivors [69]
while the figure was between 9.4 and 13.3 in Denmark
[39] and 13.5 in the Netherlands [70].
The use of endogenous treatment-regression models
showed no statistically significant relationship between
completing ADs and costs, whilst controlling for the
joint effect of other variables. The regression results also
show that when costs were split up into different cost
components, none of these costs showed a statistically
significant relationship with competing ADs. In line with
previous research [19, 40–42], there was some evidence
from our study suggesting that the decision to complete
ADs was influenced by age, depressive symptoms and
gender. This therefore implied that treating this decision
as an endogenous effect in our models was appropriate.
Though some research suggests that ADs could reduce
inappropriate over-investigation and over-treatment of
patients, leading to significant cost savings for the health
system [26, 29, 32, 36–38], our results suggest that com-
pletion of ADs did not impact the costs of healthcare
provision but were cost neutral. This lack of association
between costs and completion of ADs has however been
shown in a few other studies [27, 28, 30, 31, 33–35] and
could be due to a number of factors. Firstly, a recent sys-
tematic review [71] has shown that the effects of ADs
seem to be related to an increased frequency of out-of-
hospital care aimed at increasing the patient’s comfort
instead of prolonging their life. Compared with in-
hospital care, this type of care is relatively inexpensive
and hence does not affect the overall healthcare costs
significantly. Similar to this review, our study indicated
that the only costs that were higher for AD completers,
in comparison to AD non-completers, were consultation
costs (though this result was statistically insignificant)
the majority of which are for out-of-hospital visits. Sec-
ondly, there is a view that clinical uncertainty at the end
of life may mean that resource utilisation is unchanged
until prognosis is clearer and physicians, patients and
SDMs are certain about either going ahead with expen-
sive treatment or withdrawing it [34]. This means that
until such time, costs between AD completers and non-
completers are unlikely to be significantly different. It is
also possible that the structural barriers in access to care
identified as characterising the delivery of end of life
care [72] may mean that completing ADs does not read-
ily lead to substantial cost movements as healthcare
service utilisation does not change substantially. Such
barriers could include cultural or ethnic norms as well
as limited access to care for geographic or financial rea-
sons [72]. Further, ADs can sometimes be too specific to
account for significant changes in medical treatment and
associated healthcare costs [17, 73]. Lastly, our result
may also be reflective of the lack of fuller integration of
AD policies and procedures within the South Australian
health system needed to make the system more respon-
sive and ensure that AD implementation occurs at both
the micro and macro level rather than at just the former.
Results from the SUPPORT trial found that efforts to
improve end of life decision making need to focus on
greater individual and societal approaches if established
practices are to be changed [74, 75]. Hickman et al. [76]
also suggest that for “…advance directives to be effective,
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they need to be integrated into each part of the system
of care, including emergency medical service protocols
and regulations.”
This study had some limitations. The total follow
up period of 12 months was relatively short so the
longer-term relationship between ADs, costs and other
variables is not known. In addition, we did not have infor-
mation on whether medical care after completion of ADs
was consistent with the preferences expressed within these
ADs, which would have given a much more accurate pic-
ture of healthcare utilisation and associated costs. A lon-
ger follow-up period and/or model-based extrapolation
would be helpful in this regard and should be considered
in future research. There was a proportion of missing data
relating to resource use and other patient variables. How-
ever, robust statistical imputation methods were employed
to deal with these missing data and the results from the
imputed data and complete case analysis are broadly simi-
lar. Costs for residential aged care and other support
services for this population are likely to be substantial but
these were not included as robust data on these costs were
not collected as part of the trial. There is also large vari-
ation around the mean estimates, particularly relating to
the cost data, which is to be expected because this study
has a relatively small sample size. Consequently, a larger
cohort is needed to substantiate these preliminary find-
ings. Finally, Advance Care Planning (ACP) has been gain-
ing prominence in Australia due to a recent shift from
documentation towards the process of ACP [77]. Advance
Directives are only a small part of ACP and therefore
future research should consider exploring the relationship
between healthcare costs and ACP to gain a much broader
understanding of how decisions about end of life care
impact on healthcare costs.
Conclusion
This study has documented, and confirmed, the substan-
tial pharmaceutical, hospital and other costs associated
with caring for older people nearing the end of life. How-
ever no significant association was found between health
care utilisation costs and ADs. If one of the rationales for
the introduction of ADs is improving the end of life ex-
perience for older people and their families whilst being
cost neutral with regards to healthcare expenditures on
older people, then this study provides some evidence to
support this proposition. However, further research is
needed to substantiate these findings in larger and more
diverse clinical cohorts of frail older people.
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